Implantation Of Vaginal Construct For Patients With Vaginal Aplasia
Phase 1 Trial Of Implantation Of Vaginal Construct For Patients With Vaginal Aplasia
Wake Forest University Health Sciences
10 participants
Jun 1, 2023
INTERVENTIONAL
Conditions
Summary
In this Phase 1, single site, clinical trial, Vulvar/vaginal Smooth muscle cells (SMC) and Epithelial Cells (EPC) are isolated from autologous patient's biopsy
Eligibility
Inclusion Criteria4
- Diagnosed with congenital Mullerian duct anomaly that includes absence or obliteration of all or part of the vagina, as confirmed on pelvic MRI
- Females between the ages of 15 and 45 years
- Patients with stable medical comorbidities
- Patients that are willing to comply with all study instructions and are willing to return for study follow-up visits
Exclusion Criteria18
- Patients with a history of surgery in the target area more recent than the last 6 months
- Patients with an active vaginal area infection or urinary infection as evidenced by clinical exam or culture result
- Patients with a history of keloid scarring
- Patients who are currently taking anti-platelet medications or blood thinners
- Patients with a history of clotting disorder
- Patients with autoimmune disease or immune disorder
- Patients requiring concomitant use of or treatment with immunosuppressive agents
- Patients with a history of systemic conditions, including but not limited to HIV, thrombocytopenia, uncontrolled diabetes and chronic liver disease (including Hepatitis B or C), that the Investigator believes may jeopardize the safety of the patient to participate in the study
- Patients with evidence or diagnosis of any primary coagulation disorder (including concomitant anticoagulation therapy at enrollment)
- Patients who have been treated with any other investigational drug or participated in any investigational study within 30 days prior to enrollment in this study
- Patients with neurological disorders (e.g., multiple sclerosis, Parkinson's disease)
- Patients who are current tobacco users
- Patients with alcohol/drug abuse problems
- Patients with any systemic disease
- Patients with any psychiatric disorders
- Inability to participate in all necessary study activities due to physical or mental limitations.
- Any circumstance in which the investigator deems participation in the study is not in the subject's best interest
- If a vital sign or lab value results in exclusion, the subject could be rescreened later
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
biologic Tissue Engineered Vagina (TEV), which provides an epithelial layer for the luminal aspect and a smooth muscle layer for protecting the openness of the hollow tube, mimicking the cellular orientation and architecture of the vagina. Autologous cells isolated from vagina/vulva remnants offset any potential for immunological rejection.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05675722